EMEA and the evaluation of health-related quality of life data in the drug regulatory process (Q30965669)

27 June 2017

1 reference

title

EMEA and the evaluation of health-related quality of life data in the drug regulatory process (English)

1 reference

27 June 2017

1 reference

Sotiria Papanicolaou

1

1 reference

27 June 2017

David Sykes

series ordinal

2

1 reference

27 June 2017

Elias Mossialos

series ordinal

3

1 reference

27 June 2017

publication date

1 January 2004

1 reference

International Journal of Technology Assessment in Health Care

27 June 2017

published in

1 reference

27 June 2017

volume

20

1 reference

27 June 2017

issue

3

1 reference

27 June 2017

page(s)

311-324

1 reference

Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV).

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0266462304001138

Inter-rater reliability of a modified Karnofsky Scale of Performance Status for HIV-infected individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462304001138

Decision validity should determine whether a generic or condition-specific HRQOL measure is used in health care decisions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462304001138

Quality of life in patients with ovarian cancer: current state of research

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462304001138

Recommendations for evaluating the validity of quality of life claims for labeling and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462304001138

The standard of reporting of health-related quality of life in clinical cancer trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462304001138

US regulation of pharmaceutical outcomes research

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462304001138

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462304001138

Commentary on Jack Dowie, "Decision validity should determine whether a generic or condition-specific HRQOL measure is used in health care decisions".

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462304001138

Cancer-specific worry interference in women attending a breast and ovarian cancer risk evaluation program: impact on emotional distress and health functioning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462304001138

The clinical significance of quality-of-life results: practical considerations for specific audiences

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462304001138

Assessing clinical significance in measuring oncology patient quality of life: introduction to the symposium, content overview, and definition of terms

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462304001138

Regulatory issues for health-related quality of life--PhRMA Health Outcomes Committee workshop, 1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462304001138

The addition of mood and anxiety domains to the University of Washington quality of life scale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462304001138

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462304001138

Recommendations on health-related quality of life research to support labeling and promotional claims in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462304001138

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462304001138

Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462304001138

Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials: report of a workshop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462304001138

Reassessing quality-of-life instruments in the evaluation of new drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462304001138

inferred from DOI database lookup

7 January 2021

based on heuristic

Regulation of pharmacoeconomics and outcomes research

1 reference

https://api.crossref.org/works/10.1017%2FS0266462304001138

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1017/S0266462304001138

1 reference

27 June 2017

1 reference